Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

JP Morgan Maintains Neutral on Ormat Technologies, Raises Price Target to $80

JP Morgan analyst Mark Strouse maintains Ormat Technologies (NYSE:ORA) with a Neutral and raises the price target from $77 to $80.

byBenzinga Newsdesk

July 20, 2022

1 minute read

JP Morgan analyst Mark Strouse maintains Ormat Technologies (NYSE:ORA) with a Neutral and raises the price target from $77 to $80.

Credit Suisse Downgrades AZEK Co to Neutral

By Benzinga Newsdesk

Today, 10:52 AM

Credit Suisse analyst Daniel Oppenheim downgrades AZEK Co (NYSE:AZEK) from Outperform to Neutral.

AZEK

News

Meta Platforms CFO On Apple Privacy Changes Says Co. Is Getting Benefit Of More Favorable Comps In Q3 But Is Being Offset By Macro Environment

By Michael Horton

Today, 10:52 AM

-Reuters

Stephens & Co. Maintains Overweight on Ruth’s Hospitality Group, Maintains $20 Price Target

By Benzinga Newsdesk

Today, 10:52 AM

Stephens & Co. analyst Joshua Long maintains Ruth's Hospitality Group (NASDAQ:RUTH) with a Overweight and maintains $20 price target.

RUTH

Kiromic BioPharma Q1 EPS $(0.48) Up From $(0.53) YoY

By Benzinga Newsdesk

Today, 10:52 AM

Kiromic BioPharma (NASDAQ:KRBP) reported quarterly losses of $(0.48) per share. This is a 9.43 percent increase over losses of $(0.53) per share from the same period last year.

KRBP

JP Morgan Maintains Neutral on Ormat Technologies, Raises Price Target to $80

Related Posts

Credit Suisse Downgrades AZEK Co to Neutral

Meta Platforms CFO On Apple Privacy Changes Says Co. Is Getting Benefit Of More Favorable Comps In Q3 But Is Being Offset By Macro Environment

Stephens & Co. Maintains Overweight on Ruth’s Hospitality Group, Maintains $20 Price Target

Kiromic BioPharma Q1 EPS $(0.48) Up From $(0.53) YoY